Unity Biotechnology Overview
- Founded
-
2009
- Status
-
Public
- Employees
-
65
- Stock Symbol
-
UBX
- Investments
-
1
- Share Price
-
$1.37
- (As of Tuesday Closing)
Unity Biotechnology General Information
Description
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases.
Contact Information
Website
www.unitybiotechnology.com
Formerly Known As
Cenexys
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 285 East Grand Avenue
- South San Francisco, CA 94080
- United States
+1 (650) 000-0000
Unity Biotechnology Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.37 | $1.29 | $0.55 - $3.64 | $89.8M | 69.7M | 2.46M | -$0.95 |
Unity Biotechnology Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 11,048 | 59,209 | 204,996 | 218,266 |
| Revenue | 5,020 | 4,784 | 0 | 0 |
| EBITDA | (53,385) | (54,748) | (90,299) | (82,766) |
| Net Income | (59,195) | (60,725) | (93,844) | (82,177) |
| Total Assets | 97,593 | 124,712 | 156,319 | 151,221 |
| Total Debt | 48,330 | 55,936 | 63,496 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Unity Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Unity Biotechnology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Unity Biotechnology Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focu
Biotechnology
South San Francisco, CA
65
As of 2021
00000
000000 - 000
00000
000000
is nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate veli
0000000000000
Alameda, CA
000.00
0000000000
000.00
00000
iam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute ir
0000 000000000
Seattle, WA
00
As of 0000
00.00
0000000000 0
00.00
Add Comparison
Unity Biotechnology Competitors (4)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Recyte Therapeutics | Angel-Backed | Alameda, CA | 000.00 | 0000000000 | 000.00 | |
| 00000 000000000000 | Venture Capital-Backed | Seattle, WA | 00 | 00.00 | 0000000000 0 | 00.00 |
| 0000 000000000000 | Venture Capital-Backed | Chicago, IL | 0 | 000 | 0000000000 | 000 |
| 000000 | Formerly VC-backed | Honolulu, HI | 00 | 000.00 | 000000000 | 000.00 |
Unity Biotechnology Patents
Unity Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020385991-A1 | Antibodies directed to tie-2 and methods of use | Pending | 21-Nov-2019 | 00000000000 | |
| CA-3162181-A1 | Antibodies directed to tie-2 and methods of use | Pending | 21-Nov-2019 | 000000000 | |
| US-20210155697-A1 | Antibodies directed to tie-2 and methods of use | Pending | 21-Nov-2019 | 000000000 | |
| US-20210379078-A1 | Killing senescent cells and treating senescence-associated conditions using a bcl inhibitor and an mcl-1 inhibitor | Abandoned | 30-Oct-2018 | 000000000 | |
| US-20190382371-A1 | Acyl sulfonamides that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer | Granted | 13-Jun-2018 | C07D401/10 |
Unity Biotechnology Executive Team (23)
Unity Biotechnology Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| Anirvan Ghosh Ph.D | Unity Biotechnology | Chief Executive Officer & Board Member | 000 0000 |
| Camille Samuels | Venrock | Board Member and Member of Audit Committee | 000 0000 |
| Keith Leonard Jr. | Unity Biotechnology | Chairman | 000 0000 |
| Margo Roberts Ph.D | Unity Biotechnology | Board Member and Member of Nominating and Corporate Governance Committee and Science Committee | 000 0000 |
| Michael Samar | Self | Board Member | 000 0000 |
Unity Biotechnology Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Unity Biotechnology Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Unity Biotechnology Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 0000000 | 01-Feb-2016 | 00000 0000 | Media and Information Services (B2B) |